Minimally Invasive Endovascular Delivery of PLGA Nanoparticles to the Different Organs and Tissues
Olga A. Sindeeva, 1, Lyubov I. Kazakova, 2, Aleksandra Sain, 1, Olga I. Gusliakova 1,3, Oleg A. Kulikov, 4, Daria Terenteva, 1, Irina A. Gololobova, 4, Gleb B. Sukhorukov, 1,2; 1Skolkovo Institute of Science and Technology, Moscow, Russia; 2 Life Improvement by Future Technologies Center, Moscow, Russia; 3Saratov State University, Saratov, Russia; 4National Research Ogarev Mordovia State University, Saransk, Russia
Abstract
Intravenous administration of nanoparticles (NPs) is relatively effective for targeting the lungs and liver, but delivery to other organs remains limited. In this study, we explored alternative administration routes to enhance organ-specific accumulation of poly(lactic-co-glycolic acid) (PLGA) NPs (100 nm, negatively charged, Cy7-labeled). PLGA-Cy7 NPs showed minimal cytotoxicity at high concentrations in Hek 239, mMSCs, C2C12, L929, and Raw 264.7 cell lines, along with favorable hemocompatibility. Targeted administration via the carotid, renal, and femoral arteries significantly increased NP accumulation in the ipsilateral brain hemisphere, kidney, and hind paw by 29.5-, 15-, and 4.3-fold, respectively, compared to intravenous injection. Importantly, intra-arterial delivery under optimized conditions did not induce adverse effects such as blood flow disruption, morphological alterations, or irreversible vessel embolization. These findings demonstrate that minimally invasive intra-arterial administration provides an effective strategy for organ-specific nanoparticle delivery, supporting its potential as a platform for sustained drug release in combination with advances in materials science and endovascular techniques.
This work was supported by a grant from the Russian Science Foundation (RSF grant 23-75-10070).
Speaker
Olga A. Sindeeva
Skolkovo Institute of Science and Technology
Russia
Discussion
Ask question
